The FDA has set May 31 as the date of the first hearing on CBD. The agency is figuring out how to regulate the cannabis product that was recently legalized, including labeling, manufacturing, and marketing. The FDA prohibits adding CBD to food and drinks, but allows it in homeopathic products. (CNBC)

Walgreens’ Q2 earnings missed estimates, and the chain lowered its forecast for 2019. The drugstore’s adjusted forecast predicted flat growth this year, compared to a previous prediction of 7% to 12% growth. In Q2, Walgreens reported $34.5 billion in revenue. Its shares fell more than 12% on Tuesday. (CNBC)

The Sackler family has asked a judge to throw out an opioid lawsuit. The Sacklers argued that Massachusetts’ attorney general mischaracterized internal records to give the impression that family members directed Purdue Pharma’s marketing of opioids. The Massachusetts suit is the only one that seeks to hold the owners of Purdue personally responsible for the opioid crisis. (Reuters)

President Donald Trump has put off major healthcare reform until after the 2020 election. Trump said in a series of tweets on Monday night that Republicans are developing a health plan to surpass the Affordable Care Act, but will wait until after the 2020 election, when Trump expects to win another term and take back the House of Representatives. (Reuters)

Experts are flagging health startups that market off-label uses of depression and blood-pressure drugs. Hims sells a generic version of the antidepressant Zoloft to treat premature ejaculation, and Kick Health sells a blood-pressure drug to treat anxiety. Some experts are concerned about the startups complying with FDA regulations. (Bloomberg)